Ben Fidler
Supply Chain Dive
Virginia, United States
Contact Ben
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Ben:
US orders government to prioritize domestic drug supply chain
A directive announced by the president Thursday would require government agencies to buy certain "essential" drugs from factories in the U.S. How easily such an order would be implemented isn't clear. → Read More
Xconomy: Enanta Steps Forward in NASH Race, With Unclear Prospects
Enanta Pharmaceuticals late Wednesday became the latest of a number of companies to tout an emerging potential therapy for nonalcoholic steatohepatitis, → Read More
Xconomy: MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
The Medicines Co. this morning inched closer to bringing a twice-yearly cholesterol-lowering drug to market, touting a positive result in two more Phase 3 → Read More
Xconomy: Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
For decades, advanced lung cancer was a quick death sentence. That’s no longer a given, thanks in part to the arrival of immunotherapy. If a medical → Read More
Xconomy: Herceptin Inventors, Immunology Pioneers Take Home 2019 Lasker Awards
This year’s Lasker Awards, the US’s most prestigious biomedical honor, are going to five scientists whose work led to a critical breast cancer treatment → Read More
Xconomy: As New CEO of Cerevel, Coles Moves From One Neuro Startup to Another
Tony Coles, the biotech veteran who once steered Onyx Pharmaceuticals into a $10 billion buyout, has left one neurology startup to join another. Coles on → Read More
Xconomy: At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More
The treatment landscape for lung cancer has shifted significantly over the past few years, and more changes could be on the way. At the World Conference → Read More
Xconomy: With FDA’s Eye on JAK Drugs, Concert Moves One Ahead For Hair Loss
Despite the safety concerns that have recently emerged for class of drugs known as JAK inhibitors, their reach continues to grow. The latest example comes → Read More
Xconomy: As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
The Medicines Co. (NASDAQ: ]) announced last week that its cholesterol-lowering medicine inclisiran, meant to be taken just twice a year, had passed a key → Read More
Xconomy: $5.8B for Nothing: AbbVie Shelves Stemcentrx Drug After Latest Flop
AbbVie has officially waved the white flag on the cancer drug that triggered its $5.8 billion buyout of Stemcentrx a few years ago. North Chicago, → Read More
Xconomy: Retrophin Sinks as Drug “Pharma Bro” Martin Shkreli Co-Invented Fails
Retrophin, the drug developer founded by jailed former biotech executive Martin Shkreli, has failed its first big test. The San Diego-based company’s → Read More
Xconomy: FDA Rejects Sarepta’s Second Duchenne Drug, Citing Safety Concerns
Sarepta Therapeutics won one of the most dramatic and controversial drug approvals in the history of the FDA a few years ago. It didn’t have the same luck → Read More
Xconomy: Four New Drugs are Around the Corner. Here's What You Need to Know.
The Food and Drug Administration approved 59 new drugs last year, a record for the agency which over the years has swung back and forth between tight → Read More
Xconomy: Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
Deciphera Pharmaceuticals this morning announced plans to seek FDA approval of a cancer medicine that treats a deadly type of tumor that forms in the → Read More
Xconomy: Bio Roundup: Surprise News, a Gene Therapy Mess & a CAR-T Step
Gene therapy has become one of the hottest fields in biomedicine, with two treatments approved in the US already and several more on the way. But surprise → Read More
Xconomy: Bayer Buys Out BlueRock, Betting at Least $240M More on Cell Therapy Work
Versant Ventures and Bayer have started several biotechs together. But today marks the first time the German drug maker takes a step further and buys one → Read More
Xconomy: FDA: Despite “Manipulated” Data, $2M Gene Therapy Should Stay on Market
The FDA on Tuesday said that some data supporting the spinal muscular atrophy gene therapy Zolgensma was “manipulated” before its May 24 approval and that → Read More
Xconomy: GlycoMimetics Sickle Cell Drug Flops as Others Creep Forward
New treatments could soon be on the way for sickle cell disease, an inherited and debilitating blood disorder. But a drug from GlycoMimetics won’t be → Read More
Xconomy: Amicus Offers First Look At Gene Therapy Work With Batten’s Data
Amicus Therapeutics bought a spinout of Nationwide Children’s Hospital last year as part of a plan to become a player in the emerging field of gene → Read More
Xconomy: Merck Data Are Another Step for Immunotherapy in Breast Cancer
Merck this morning announced that a combination of its drug pembrolizumab (Keytruda) and chemotherapy succeeded in a Phase 3 study in breast cancer, a → Read More